Regenxbio logo

Regenxbio (RGNX) Q1 2026 Earnings

RGNX·Reported May 14, 2026·Before market open

Regenxbio reported Q1 2026 revenue of $6.4M (-92.8% YoY), missed analyst consensus of $25.8M by $19.4M. Diluted EPS came in at $-1.72, missed the $-1.36 consensus by $0.36.

Revenue
$6.4Mmissed by $19.4M
Consensus: $25.8M
Diluted EPS
$-1.72missed by $0.36
Consensus: $-1.36
SEC

SEC Filings

Earnings release8-K · 0001193125-26-222768
Quarterly report10-Q · 0001193125-26-222804

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Regenxbio's Q1 2026 earnings report.

Regenxbio (RGNX) reported Q1 2026 earnings on May 14, 2026 before market open.

Regenxbio reported revenue of $6.4M and diluted EPS of $-1.72 for Q1 2026.

Revenue missed the consensus estimate of $25.8M by $19.4M. EPS missed the consensus estimate of $-1.36 by $0.36.

Compared to the same quarter a year prior, revenue declined 92.8% from $89.0M a year earlier.

You can read the 8-K earnings release (0001193125-26-222768) and the 10-Q periodic report (0001193125-26-222804) directly on SEC EDGAR. The filing index links above go to sec.gov.